Skip to main content
May 04, 2020
People with low mood and a history of depression tend not to use mood-modifying activities to stabilize mood, according to research published online in JAMA Psychiatry.
April 20, 2020
Depression is “vastly underdiagnosed” in people with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), states a literature review published online in the Harvard Review of Psychiatry.
April 13, 2020
The protein GPR56 may provide an easy-to-measure biomarker of a patient’s response to antidepressants as well as a novel drug target for the treatment of major depressive disorder, according to a published study.
March 16, 2020
Women who had depressive symptoms during their third trimester of pregnancy, or persistently before and after giving birth, were twice as likely to have babies with very low levels of immunoglobulin A.
February 24, 2020
    AXS-05, an investigational modulated-delivery tablet, significantly improved symptoms of depression
February 14, 2020
Researchers have developed a machine learning algorithm that uses electroencephalogram (EEG) data to predict whether a selective serotonin reuptake inhibitor (SSRI) is likely to benefit a patient.
February 11, 2020
Patients with residual depressive symptoms who received online mindfulness-based cognitive therapy (MBCT) plus usual care demonstrated significant gains in depression and functional outcomes, compared with patients who received usual care only.
January 31, 2020
A single dose of psilocybin combined with psychotherapy produced significant improvements in emotional and existential distress in patients with cancer that lasted more than 4 years, according to a published study.
January 15, 2020
Knowing someone with emotional or mental health problems increased the likelihood that people who screened positive for depression sought out depression treatment for themselves, according to a study published online in Psychiatric Services.
January 10, 2020
AXS-05, an investigational modulated-delivery tablet combining dextromethorphan and bupropion, significantly improved symptoms of depression in patients with major depressive disorder (MDD) in a recent phase 3 trial, announced developer Axsome Therapeutics Inc.
Back to Top